Leah R.  Neufeld net worth and biography

Leah Neufeld Biography and Net Worth

Chief People Officer of Immuneering

Ms. Neufeld has served as our Chief People Officer since October 2022. Prior to joining us, Ms. Neufeld served as Chief Human Resources Officer of Luzsana Biotechnology (“Luzsana”) from August 2021 to October 2022, where she, as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines. Previously, she was the Vice President, People, at Prevail Therapeutics from September 2019 to August 2021, until its acquisition by Eli Lilly. Prior to that, from August 2015 through September 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals, and from January 2014 to July 2015 was the Global Head of Human Resources for NPS Pharma until it was acquired by Shire Pharmaceuticals. From April 2009 to January 2014, she held positions of increasing responsibility at Daiichi Sankyo Pharma Development, most recently serving as Director of Human Resources. Earlier in her career, from November 2002 to April 2009, Ms. Neufeld held various human resources positions at Johnson & Johnson, including Manager of Human Resources in the consumer division and its oncology company called Ortho Biotech. Ms. Neufeld earned a B.A. in psychology from the American University and an M.S. in career counseling and organization development from Johns Hopkins University.

What is Leah R. Neufeld's net worth?

The estimated net worth of Leah R. Neufeld is at least $132.71 thousand as of January 13th, 2026. Ms. Neufeld owns 25,970 shares of Immuneering stock worth more than $132,707 as of May 6th. This net worth evaluation does not reflect any other assets that Ms. Neufeld may own. Learn More about Leah R. Neufeld's net worth.

How do I contact Leah R. Neufeld?

The corporate mailing address for Ms. Neufeld and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Leah R. Neufeld's contact information.

Has Leah R. Neufeld been buying or selling shares of Immuneering?

Leah R. Neufeld has not been actively trading shares of Immuneering during the past quarter. Most recently, on Tuesday, January 13th, Leah R. Neufeld bought 2,626 shares of Immuneering stock. The stock was acquired at an average cost of $4.15 per share, with a total value of $10,897.90. Following the completion of the transaction, the insider now directly owns 25,970 shares of the company's stock, valued at $107,775.50. Learn More on Leah R. Neufeld's trading history.

Who are Immuneering's active insiders?

Immuneering's insider roster includes Peter Feinberg (Director), Brett Hall (Chief Scientific Officer), Diana Hausman (Director), Leah Neufeld (Chief People Officer), Thomas Schall (Director), and Benjamin Zeskind (CEO). Learn More on Immuneering's active insiders.

Are insiders buying or selling shares of Immuneering?

In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.

Information on this page was last updated on 1/16/2026.

Leah R. Neufeld Insider Trading History at Immuneering

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/13/2026Buy2,626$4.15$10,897.9025,970View SEC Filing Icon  
10/1/2025Buy800$6.38$5,104.0023,344View SEC Filing Icon  
7/2/2025Buy700$3.57$2,499.0010,729View SEC Filing Icon  
3/20/2024Buy3,818$2.88$10,995.8410,029View SEC Filing Icon  
See Full Table

Leah R. Neufeld Buying and Selling Activity at Immuneering

This chart shows Leah R Neufeld's buying and selling at Immuneering by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immuneering Company Overview

Immuneering logo
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.10
Low: $5.06
High: $5.40

50 Day Range

MA: $5.32
Low: $4.78
High: $6.13

2 Week Range

Now: $5.10
Low: $1.10
High: $10.08

Volume

693,431 shs

Average Volume

1,388,009 shs

Market Capitalization

$329.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37